

EXHIBIT G



US009504651B2

(12) **United States Patent**
MacLachlan et al.

(10) **Patent No.:** **US 9,504,651 B2**

(45) **Date of Patent:** **Nov. 29, 2016**

(54) **LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY**

(71) Applicant: **PROTIVA BIOTHERAPEUTICS, INC.**, Burnaby (CA)

(72) Inventors: **Ian MacLachlan**, Mission (CA); **Lloyd Jeffs**, Burnaby (CA); **Lorne R. Palmer**, Burnaby (CA); **Cory Giesbrecht**, Vancouver (CA)

(73) Assignee: **PROTIVA BIOTHERAPEUTICS, INC.**, Burnaby (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 15 days.

(21) Appl. No.: **14/304,578**

(22) Filed: **Jun. 13, 2014**

(65) **Prior Publication Data**

US 2014/0294937 A1 Oct. 2, 2014

Related U.S. Application Data

(60) Continuation of application No. 13/684,066, filed on Nov. 21, 2012, which is a continuation of application No. 12/965,555, filed on Dec. 10, 2010, now Pat. No. 8,329,070, which is a division of application No. 10/611,274, filed on Jun. 30, 2003, now Pat. No. 7,901,708.

(60) Provisional application No. 60/392,887, filed on Jun. 28, 2002.

(51) **Int. Cl.**

A61K 47/10 (2006.01)
A61K 47/24 (2006.01)
B01J 13/04 (2006.01)
A61K 9/127 (2006.01)
A61K 47/48 (2006.01)
A61K 31/7084 (2006.01)
A61K 31/7088 (2006.01)
A61K 47/44 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/1271** (2013.01); **A61K 9/127** (2013.01); **A61K 9/1277** (2013.01); **A61K 31/7084** (2013.01); **A61K 31/7088** (2013.01); **A61K 47/10** (2013.01); **A61K 47/24** (2013.01); **A61K 47/44** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,394,448 A 7/1983 Szoka, Jr. et al.
4,438,052 A 3/1984 Weder et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2041075 A1 10/1991
CA 2309727 A1 4/1999

(Continued)

OTHER PUBLICATIONS

Lasic, D. D. "Novel applications of Liposomes" Tibtech, 1998, v. 16, 307-321.*

(Continued)

Primary Examiner — Mina Haghighatian


Assistant Examiner — Erin Hirt

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

14 Claims, 15 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

4,515,736	A	5/1985	Deamer	7,982,027	B2	7/2011	MacLachlan et al.
4,598,051	A	7/1986	Papahadjopoulos et al.	8,058,068	B2	11/2011	Hawley-Nelson et al.
4,687,661	A	8/1987	Kikuchi et al.	8,058,069	B2*	11/2011	Yaworski et al. 435/458
4,897,355	A	1/1990	Eppstein et al.	8,158,827	B2	4/2012	Chu et al.
5,013,556	A	5/1991	Woodle et al.	8,227,443	B2	7/2012	MacLachlan et al.
5,171,678	A	12/1992	Behr et al.	8,283,333	B2*	10/2012	Yaworski et al. 514/44 A
5,208,036	A	5/1993	Eppstein et al.	8,329,070	B2*	12/2012	MacLachlan A61K 9/127
5,225,212	A	7/1993	Martin et al.				264/4.1
5,264,618	A	11/1993	Felgner et al.	8,466,122	B2*	6/2013	Heyes et al. 514/44 A
5,279,833	A	1/1994	Rose	8,492,359	B2*	7/2013	Yaworski et al. 514/44 A
5,283,185	A	2/1994	Epanand et al.	9,005,654	B2	4/2015	MacLachlan et al.
5,320,906	A	6/1994	Eley et al.	9,006,417	B2	4/2015	Yaworski et al.
5,334,761	A	8/1994	Gebeyehu et al.	2001/0048940	A1	12/2001	Tousignant et al.
5,424,073	A	6/1995	Rahman et al.	2003/0069173	A1	4/2003	Hawley-Nelson et al.
5,478,860	A	12/1995	Wheeler et al.	2003/0072794	A1	4/2003	Boulikas
5,545,412	A	8/1996	Eppstein et al.	2003/0077829	A1	4/2003	MacLachlan
5,552,157	A	9/1996	Yagi et al.	2003/0083272	A1	5/2003	Wiederholt et al.
5,578,475	A	11/1996	Jessee	2003/0124033	A1	7/2003	Baker et al.
5,593,622	A*	1/1997	Yoshioka A61K 9/1271 264/4.3	2003/0143732	A1	7/2003	Fosnaugh et al.
				2004/0032037	A1	2/2004	Katinger et al.
5,627,159	A	5/1997	Shih et al.	2004/0037874	A1	2/2004	Hong et al.
5,641,662	A	6/1997	Debs et al.	2004/0063654	A1	4/2004	Davis et al.
5,653,996	A	8/1997	Hsu	2004/0142025	A1	7/2004	MacLachlan et al.
5,656,743	A	8/1997	Busch et al.	2004/0142892	A1	7/2004	Finn et al.
5,674,908	A	10/1997	Haces et al.	2004/0253723	A1	12/2004	Tachas et al.
5,703,055	A	12/1997	Felgner et al.	2004/0259247	A1	12/2004	Tuschi et al.
5,705,385	A*	1/1998	Bally et al. 435/320.1	2005/0064595	A1	3/2005	MacLachlan et al.
5,736,392	A	4/1998	Hawley-Nelson et al.	2005/0118253	A1	6/2005	MacLachlan et al.
5,820,873	A	10/1998	Choi et al.	2005/0260757	A1	11/2005	Gebeyehu et al.
5,830,430	A*	11/1998	Unger et al. 424/1.21	2006/0058249	A1	3/2006	Tong et al.
5,877,220	A	3/1999	Schwartz et al.	2006/0147514	A1	7/2006	Gebeyehu et al.
5,885,613	A	3/1999	Holland et al.	2006/0228406	A1	10/2006	Chiou et al.
5,958,901	A	9/1999	Dwyer et al.	2007/0042031	A1	2/2007	MacLachlan et al.
5,976,567	A	11/1999	Wheeler et al.	2007/0202598	A1	8/2007	Chu et al.
5,981,501	A	11/1999	Wheeler et al.	2007/0202600	A1	8/2007	Chu et al.
6,007,838	A	12/1999	Alving et al.	2008/0200417	A1	8/2008	Semple et al.
6,020,202	A	2/2000	Jessee	2009/0143583	A1	6/2009	Chu et al.
6,034,135	A	3/2000	Schwartz et al.	2009/0191259	A1	7/2009	Li et al.
6,051,429	A	4/2000	Hawley-Nelson et al.	2010/0159593	A1	6/2010	Chu et al.
6,075,012	A	6/2000	Gebeyehu et al.	2011/0216622	A1	9/2011	MacLachlan et al.
6,093,348	A	7/2000	Kowalski et al.	2012/0136073	A1	5/2012	Yang et al.
6,165,501	A	12/2000	Tirosh et al.	2012/0238747	A1	9/2012	Chu et al.
6,172,049	B1	1/2001	Dwyer et al.	2013/0303587	A1	11/2013	Yaworski et al.
6,251,939	B1	6/2001	Schwartz et al.	2014/0044772	A1*	2/2014	MacLachlan A61K 9/127 424/450
6,284,267	B1	9/2001	Aneja				
6,287,591	B1	9/2001	Semple et al.	2016/0032320	A1	2/2016	Yaworski et al.
6,339,173	B1	1/2002	Schwartz et al.				
6,376,248	B1	4/2002	Hawley-Nelson et al.				
6,534,484	B1	3/2003	Wheeler et al.				
6,586,410	B1	7/2003	Wheeler et al.				
6,596,305	B1	7/2003	Edgerly-Plug				
6,638,529	B2	10/2003	Schwartz et al.				
6,649,780	B1	11/2003	Eibl et al.				
6,671,393	B2	12/2003	Hays et al.				
6,696,424	B1	2/2004	Wheeler et al.				
6,734,171	B1*	5/2004	Saravolac A61K 48/0008 424/450				
6,815,432	B2	11/2004	Wheeler et al.				
6,835,395	B1	12/2004	Semple et al.				
6,843,942	B2	1/2005	Katinger et al.				
6,858,224	B2	2/2005	Wheeler et al.				
7,166,745	B1	1/2007	Chu et al.				
7,341,738	B2	3/2008	Semple et al.				
7,422,902	B1	9/2008	Wheeler et al.				
7,479,573	B2	1/2009	Chu et al.				
7,601,872	B2	10/2009	Chu et al.				
7,641,915	B2	1/2010	Chen et al.				
7,687,070	B2	3/2010	Gebeyehu et al.				
7,745,651	B2	6/2010	Heyes et al.				
7,799,565	B2*	9/2010	MacLachlan et al. 435/458				
7,803,397	B2	9/2010	Heyes et al.				
7,807,815	B2	10/2010	MacLachlan et al.				
7,901,708	B2*	3/2011	MacLachlan A61K 9/127				

FOREIGN PATENT DOCUMENTS

CA	2271582	A1	11/1999
CA	2330741	A1	11/1999
CA	2397016	A1	7/2001
CA	2457959	A1	12/2002
CA	2427640	A1	5/2003
CA	2473135	A1	6/2003
CA	2490983	A1	1/2004
CA	2491164	A1	1/2004
CA	2513623		8/2004
EP	0 055 576	A1	7/1982
EP	1 013 268	A	6/2000
EP	1 203 614	A1	11/2000
IE	911350		4/1991
JP	03-126211		5/1991
JP	05-202085		8/1993
JP	06-080560		3/1994
JP	02-525063		8/2002
JP	03-505401		2/2003
JP	07-524349		8/2007
WO	89/07929	A1	9/1989
WO	91/16024	A1	10/1991
WO	91/16039	A1	10/1991
WO	93/05162	A1	3/1993
WO	93/09236	A1	5/1993
WO	93/12240	A1	6/1993
WO	93/12756	A2	7/1993
WO	93/24640	A2	12/1993
WO	93/25673	A1	12/1993

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	95/35301	A1	12/1995	
WO	96/02655	A1	2/1996	
WO	96/10390	A1	4/1996	
WO	96/40964	A2	12/1996	
WO	96/41873	A1	12/1996	
WO	98/51278	A2	† 11/1998	
WO	98/51285	A2	11/1998	
WO	WO 9851278	A2	* 11/1998 A61K 9/00
WO	99/14346	A2	3/1999	
WO	00/03683	A2	1/2000	
WO	00/15820	A1	3/2000	
WO	00/29103	A1	5/2000	
WO	00/62813	A2	10/2000	
WO	01/05373	A1	1/2001	
WO	01/05374	A1	1/2001	
WO	01/05873	A1	1/2001	
WO	01/75164	A2	10/2001	
WO	01/93836	A1	12/2001	
WO	02/34236	A2	5/2002	
WO	02/43699		6/2002	
WO	02/43699	A2	6/2002	
WO	02/085434	A1	10/2002	
WO	02/087541	A1	11/2002	
WO	03/059381	A2	7/2003	
WO	03/097805	A2	11/2003	
WO	2004/002453	A1	1/2004	
WO	2004/065546	A2	8/2004	
WO	2004/110499	A1	12/2004	
WO	2005/007196	A2	1/2005	
WO	2005/026372	A1	3/2005	
WO	2005/120152	A2	12/2005	
WO	2015/011633	A1	1/2015	

OTHER PUBLICATIONS

Meyer, O. et al. "Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides." *J. Biol. Chem.* 1998, 273, 15621-15627.*

Arpicco, S., et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," *Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society, Inc.)*, 1999, vol. 26, pp. 759-760.

Arpicco, S., et al., "Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids," *IL Farmaco*, 2004, vol. 59, pp. 869-878.

Ballas, N., et al., "Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts," *Biochimica et Biophysica Acta*, 1988, vol. 939, pp. 8-18.

Barinaga, M., "Step Taken Toward Improved Vectors for Gene Transfer," *Science*, 1994, vol. 266, p. 1326.

Bass, "The short answer," *Nature*, 2001, vol. 411, pp. 428-429.

Batzri et al. "Single Bilayer Liposomes Prepared without Sonication," *Biochimica et Biophysica Acta* 1973, vol. 298, pp. 1015-1019.

Beale, G., et al., "Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti-EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization-accessible Region using the Same Delivery System," *Journal of Drug Targeting*, 2003, vol. 11, No. 7, pp. 449-456.

Behr, J.-P., "Synthetic Gene-Transfer Vectors," *Acc. Chem. Res.*, 1993, vol. 26, pp. 274-278.

Brigham, K., et al., "Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle," *The American Journal of the Medical Sciences*, vol. 298, No. 4, pp. 278-281, 1989.

Brummelkamp et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," *Science*, 2002, vol. 296, pp. 550-553.

Cevc, G., "How Membrane Chain-Melting Phase-Transition Temperature is Affected by the Lipid Chain Asymmetry and Degree of

Chonn et al., "Recent advances in liposomal drug-delivery systems," *Current Opinion in Biotechnology*, 1995, pp. 698-708, vol. 6.

Cortesi, R., et al., "Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA," *International Journal of Pharmaceutics*, 1996, vol. 139, pp. 69-78.

Crystal, R., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," *Science*, 1995, vol. 270, pp. 404-410.

Culver K., "The First Human Gene Therapy Experiment," *Gene Therapy: A Handbook for Physicians*, 1994, pp. 33-40.

Duzgunes, N., "Membrane Fusion," *Subcellular Biochemistry*, 1985, vol. 11, pp. 195-286.

Dwarki, V.J., et al., "Cationic Liposome-Mediated RNA Transfection," *Methods in Enzymology*, 1993, vol. 217, pp. 644-654.

Elbashir, S. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," *Nature*, 411(24):494-498 (May 2001).

Enoch, H., et al., "Formation and properties of 1000-Å-diameter, single-bilayer phospholipid vesicles," *Proc. Natl. Acad. Sci. USA*, 1979, vol. 76, No. 1, pp. 145-149.

Felgner, J., et al., "Cationic Lipid-Mediated Transfection in Mammalian Cells: 'lipofection'," *J. Tiss. Cult. Meth.*, 1993, vol. 15, pp. 63-68.

Felgner, J., et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," *The Journal of Biological Chemistry*, 1994, vol. 269, No. 4, pp. 2550-2561.

Felgner, P., et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, pp. 7413-7417.

Felgner, P.L., et al., "Cationic Liposome Mediated Transfection," *Proc. West. Pharmacol. Soc.*, 1989, vol. 32, pp. 115-121.

Gao, X., et al., "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells," *Biochem. Biophys. Res. Comm.*, 1991, vol. 179, No. 1, pp. 280-285.

Georgopapadakou, N. H., ed., "Drug Transport in Antimicrobial and Anticancer Chemotherapy," CRC Press, Marcel Dekker, Inc. (1995).

Gershon, H., et al., "Mode of Formation and Structural Feature of DNA-Cationic Liposome Complexes Used for Transfection," *Biochemistry*, 1993, vol. 32, pp. 7143-7151.

Guy-Caffey, J., et al., "Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides," *The Journal of Biological Chemistry*, 1995, vol. 270, No. 52, pp. 31391-31396.

Hawley-Nelson, P., et al., "LipofectAmine™ Reagent: A New, Higher Efficiency Polycationic Liposome Transfection Reagent," *Focus*, 1993, vol. 15, No. 3, pp. 73-80.

Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids," *Journal of Controlled Release*, 2005, vol. 107, pp. 276-287.

Heyes et al., "Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer," *J. Med. Chem.*, 2002, vol. 45, pp. 99-114.

Hirota et al., "Simple Mixing Device to Reproducibly Prepare Cationic Lipid-DNA Complexes (Lipoplexes)," *BioTechniques*, Aug. 1999, vol. 27, No. 2, pp. 286-290.

Hyde, S. et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," *Nature*, 1993, vol. 362, pp. 250-255.

Isele et al., "Large-Scale Production of Liposomes Containing Monomeric Zinc Phthalocyanine by Controlled Dilution of Organic Solvents" *Journal of Pharmaceutical Sciences*, Nov. 1994, vol. 83, No. 11, pp. 1608-1616.

Jiang, L., et al., "Comparison of protein precipitation methods for sample preparation prior to proteomic analysis," *Journal of Chromatography A*, 2004, vol. 1023, pp. 317-320.

Juliano, R., et al., "The Effect of Particle Size and Charge on the Clearance Rates of Liposomes and Liposome Encapsulated Drugs," *Biochem. Biophys. Res. Commun.*, 1975, vol. 63, No. 3, pp. 651-658.

Keough, K., "Influence of chain unsaturation and chain position on

(56)

References Cited

OTHER PUBLICATIONS

Krichevsky, A. et al., "RNAi functions in cultured mammalian neurons," *PNAS*, 99(18):11926-29, 2002.

Lawrence et al. "The formation, characterization and stability of non-ionic surfactant vesicles," *S.T.P. Pharma Sciences*, 1996, vol. 6, No. 1, pp. 49-60.

Lawrence et al., "Synthesis and aggregation properties of dialkyl polyoxyethylene glycerol ethers," *Chemistry and Physics of Lipids*, 1996, 82(2):89-100.

Legendre, J.-Y. et al., "Delivery of Plasmid DNA into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes," *Pharm. Res.*, 1992, vol. 9, No. 10, pp. 1235-1242.

Leventis, R. et al., "Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles," *Biochem. Biophys. Acta*, 1990, vol. 1023, pp. 124-132.

Liu et al., "Cationic liposome-mediated intravenous gene delivery," *J. Biol. Chem.* 1995, vol. 270, pp. 24864-24870.

MacLachlan, "Liposomal Formulations for Nucleic Acid Delivery," *Antisense Drug Technologies*, Second Edition; 2007; pp. 237-270.

Marshall, E., "Gene Therapy's Growing Pains," *Science*, 1995, vol. 269, pp. 1050-1055.

Maurer et al. "Spontaneous Entrapment of Polynucleotides upon Electrostatic Interaction with Ethanol-Destabilized Cationic Liposomes," *Biological Journal*, May 2001, vol. 80, pp. 2310-2326.

Murahashi et al., "Synthesis and evaluation of neoglycolipid for liposome modification," *Biol. Pharm. Bull.*, 1997, 20(6):704-707.

Orkin, S. et al., NIH Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.

Parr et al., Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles, *Biochimica et Biophysica Acta*, 1994, 1195:21-30.

Paul, C. et al., "Effective expression of small interfering RNA in human cells," *Nature Biotech.*, 2002, vol. 20, pp. 505-508.

Puyal, C. et al., "A new cationic liposome encapsulating genetic material: A potential delivery system for polynucleotides," *Eur. J. Biochem.*, 1995, vol. 228, pp. 697-703.

Sawada et al., "Microemulsions in supercritical CO₂ utilizing the polyethyleneglycol dialkylglycerol and their use for the solubilization of hydrophiles," *Dyes and Pigments*, 2005, pp. 64-74, vol. 65.

Semple et al. "Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures," *Biochim. Biophys. Acta*, 2001, vol. 1510, No. 1-2, pp. 152-166.

Shin et al. "Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids," *Journal of Controlled Release*, 2003, vol. 91, pp. 187-200.

Song et al., "Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense

DNA mediated by cationic lipid liposomes," *Biochimica et Biophysica Acta*, 2002, 1558:1-13.

Sorensen et al., "Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice," *J. Mol. Biol.*, Apr. 4, 2003, vol. 4, pp. 761-766.

Spagnou, S. et al., "Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNA," *Biochemistry*, 2004, vol. 43, pp. 13348-13356.

Stamatatos, L. et al., "Interactions of Cationic Lipid Vesicles with Negatively Charged Phospholipid Vesicles and Biological Membranes," *Biochemistry*, 1988, vol. 27, pp. 3917-3925.

Szoka, F. et al., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," *Ann. Rev. Biophys. Bioeng.*, 1980, vol. 9, pp. 467-508.

Szoka, F. et al., "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation," *Proc. Natl. Acad. Sci. USA*, 1978, vol. 75, No. 9, pp. 4194-4198.

Templeton, "Cationic liposome-mediated intravenous gene delivery in vivo," *Bioscience Reports*, 2002, vol. 22, No. 2, pp. 283-295.

Van Der Woude, I. et al., "Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system," *Biochimica et Biophysica Acta*, 1995, vol. 1240, pp. 34-40.

Wagner et al., "The Crossflow Injection Technique: an Improvement of the Ethanol Injection Method," *Journal of Liposome Research*, Sep. 2002, vol. 12, No. 3, pp. 259-270.

Wheeler et al., "Stabilized plasmid-lipid particles: construction and characterization," *Gene Ther.*, 1999, vol. 6, No. 2, pp. 271-281.

Wilson, R. et al., "Counterion-Induced Condensation of Deoxyribonucleic Acid. A Light-Scattering Study," *Biochemistry*, 1979, vol. 18, No. 11, pp. 2192-2196.

Woodle, M.C. et al., "Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes," *Biochimica et Biophysica Acta*, 1992, vol. 1105, pp. 193-200.

Zelphati et al., "Stable and Monodisperse Lipoplex Formulations for Gene Delivery," *Gene Therapy*, 1998, vol. 5, pp. 1272-1282.

Zhu, N. et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," *Science*, 1993, vol. 261, pp. 209-211.

Global Newswire, retrieved from <http://globalnewswire.com> on Feb. 27, 2013, Tekmira sues Alnylam Pharmaceuticals for repeated misuse of trade secrets and confidential information, Mar. 16, 2011, pp. 1-3.

Jeffs et al. "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA" *Pharmaceutical Research*, 2005, vol. 22, No. 3 pp. 362-372.

Kee, J., "e-Study guide for: Clinical calculations," *Just the Facts 101, Textbook Key Facts*, 6th Ed., 2015, 1 page.

Omega Engineering, Inc., "Omegaflex® Peristaltic Pump Model No. FPU500," retrieved online at <<https://web.archive.org/web/20010715124628/http://www.omega.com/pdf/tubing/pumps/fpu500/fpu500.asp>>, cached Jul. 15, 2001, 2 pages.

* cited by examiner

† cited by third party

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.